SEC Form 4 · accession 0001144204-17-048727
TITAN PHARMACEUTICALS INC · TTNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
M David Macfarlane
Director
Period of report
Sep 15, 2017
Accepted (ET)
Sep 19, 2017 · 6:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000910267
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $1.50 | Sep 15, 2017 | A | 10,000 | A | — | Sep 15, 2027 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The option vests in 12 equal monthly installments commencing as of September 1, 2017.